Serum sulfhydryl levels in rheumatoid patients treated with cyclophosphamide.
Six months' cyclophosphamide treatment significantly increased the sulfhydryl (SH) serum levels in all 12 rheumatoid arthritis (RA) patients studied and significantly decreased the PIP joints' technetium index (Tc-index), the erythrocyte sedimentation rate (ESR), and the joint count.
D000328:Adult; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D001799:Blood Sedimentation; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D013438:Sulfhydryl Compounds / Q000097:blood*; D013667:Technetium
D013438:Sulfhydryl Compounds; D013667:Technetium; D003520:Cyclophosphamide